Inhibition of protein synthesis by didemnin B is not sufficient to induce apoptosis in human mammary carcinoma (MCF7) cells

Biochemical Pharmacology

Volumn 58, Issue 6, 1999, Pages 1067-1074

  Beidler, David R ^a   Ahuja, Deepika ^b   Wicha, Max S ^a   Toogood, Peter L ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Apoptosis; Caspases; Cycloheximide; Didemnins; Emetine; Protein synthesis

Indexed keywords

ANTIMITOTIC AGENT; CASPASE; CYCLOHEXIMIDE; DIDEMNIN B; EMETINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE);

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN MCF 7; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PEPTIDES, CYCLIC; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN SYNTHESIS INHIBITORS; STEM CELLS; TUMOR CELLS, CULTURED;

EID: 0032788432     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00193-8     Document Type: Article

References (43)

1. Li W.-R., Joullie M.M. The didemnins Biological properties, chemistry and total synthesis . Stud Nat Prod Chem. 10:1992;241-302.
2. Rinehart K.L. Jr, Gloer J.B., Hughes R.G. Jr, Renis H.E., McGovren J.P., Swynenberg E.B., Stringfellow D.A., Kuentzel S.L., Li L.H. Didemnins Antiviral and antitumor depsipeptides from a caribbean tunicate . Science. 212:1981;933-935.
3. Jiang T.L., Liu R.H., Salmon S.E. Antitumor activity of didemnin B in the human tumor stem cell assay. Cancer Chemother Pharmacol. 11:1983;1-4.
4. Li L.H., Timmins L.G., Wallace T.L., Krueger W.C., Prairie M.D., Im W.B. Mechanism of action of didemnin B, a depsipeptide from the sea. Cancer Lett. 23:1984;279-288.
5. Sakai R., Rinehart K.L., Kishore V., Kundu B., Faircloth G., Gloer J.B., Carney J.R., Namikoshi M., Sun F., Hughes R.G. Jr, Garcia Gravalos D., de Quesada T.G., Wilson G.R., Heid R.M. Structure-activity relationships of the didemnins. J Med Chem. 39:1996;2819-2834.
6. Rinehart K.L. Jr, Gloer J.B., Wilson G.R., Hughes R.G. Jr, Li L.H., Renis H.E., McGovren J.P. Antiviral and antitumor compounds from tunicates. Fedn Proc. 42:1983;87-90.
7. Benvenuto J.A., Newman R.A., Bignami G.S., Raybould T.J., Raber M.N., Esparza L., Walters R.S. Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer. Invest New Drugs. 10:1992;113-117.
8. Cain J.M., Liu P.Y., Alberts D.E., Gallion H.H., Laufman L., O'Sullivan J., Weiss G., Bickers J.N. Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study. Invest New Drugs. 10:1992;23-24.
9. Dorr F.A., Kuhn J.G., Phillips J., Von Hoff D.D. Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide. Eur J Cancer Clin Oncol. 24:1988;1699-1706.
10. Jacobs A.J., Blessing J.A., Munoz A. A phase II trial of didemnin B (NSC No. 325319) in advanced and recurrent cervical carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 44:1992;268-270.
11. Jones D.V. Jr, Ajani J.A., Blackburn R., Daugherty K., Levin B., Patt Y.Z., Abbruzzese J.L. Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs. 10:1992;211-213.
12. Lad T., Mullane M., Swedler R., Kilton L., Johnson P., Albain K., Blough R., Weidner L. Phase II trial of didemnin B in non-small cell lung cancer. An Illinois Cancer Council study. Proc Annu Meet Am Soc Clin Oncol. 10:1991;A891.
13. Malfetano J.H., Blessing J.A., Homesley H.D., Look K.Y., McGehee R. A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Am J Clin Oncol. 19:1996;184-186.
14. Malfetano J.H., Blessing J.A., Jacobs A.J. A phase II trial of Didemnin B (NSC #335319) in patients with previously treated epithelial ovarian cancer. A Gynecologic Oncology Group study. Am J Clin Oncol. 16:1993;47-49.
15. Razis E., Mittelman A., Coombe N., Puccio C., Chun H., Ahmed T., Helson L., Cook P., Arlin Z. Phase II clinical trial of didemnin B (Dnb) in patients (Pts) with glioblastoma multiforme (Gm). Proc Annu Meet Am Soc Clin Oncol. 11:1992;A432.
16. Shin D.M., Holoye P.Y., Murphy W.K., Forman A., Papasozomenos S.C., Hong W.K., Raber M. Phase I/II clinical trial of didemnin B in non-small-cell lung cancer Neuromuscular toxicity is dose-limiting . Cancer Chemother Pharmacol. 29:1991;145-149.
17. Shin D.M., Holoye P.Y., Murphy W.K., Forman A., Papasozomenus S., Jones E., Raber M., Hong W.K. Phase I clinical trial of didemnin-B (Nsc 325319:Dn-B) in non-small cell lung cancer; neuromuscular toxicity (Nmt) is dose-limiting. Proc Annu Meet Am Soc Clin Oncol. 10:1991;A249.
18. Shin D.M., Holoye P.Y., Forman A., Winn R., Perez-Soler R., Dakhil S., Rosenthal J., Raber M.N., Hong W.K. Phase II clinical trial of didemnin B in previously treated small cell lung cancer. Invest New Drugs. 12:1994;243-249.
19. Stewart J.A., Low J.B., Roberts J.D., Blow A. A phase I clinical trial of didemnin B. Cancer. 68:1991;2550-2554.
20. Taylor S.A., Goodman P., Crawford E.D., Stuckey W.J., Stephens R.L., Gaynor E.R. Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. A Southwest Oncology Group study. Invest New Drugs. 10:1992;55-56.
21. Weiss R.B., Peterson B.L., Allen S.L., Browning S.M., Duggan D.B., Schiffer C.A. A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study. Invest New Drugs. 12:1994;41-43.
22. Williamson S.K., Wolf M.K., Eisenberger M.A., O'Rourke M., Brannon W., Crawford E.D. Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study. Invest New Drugs. 13:1995;167-170.
23. Jouin P., Poncet J., Dufour M.-N., Aumelas A., Pantaloni A. Antineoplastic activity of didemnin congeners Nordidemnin and modified chain analogues . J Med Chem. 34:1991;487-491.
24. Mayer S.C., Ramanjulu J., Vera M.D., Pfezenmayer A.J., Joullié M.M. Synthesis of new didemnin B analogues for investigations of structure/biological activity relationships (SAR). J Org Chem. 59:1994;5192-5205.
25. Sakai R., Stroh J.G., Sullins D.W., Rinehart K.L. Seven new didemnins from the marine tunicate Trididemnum solidum. J Am Chem Soc. 117:1995;3734-3748.
26. Faircloth G., Grant W., Nam S., Jimeno J., Manzanares I., Rinehart K.L. Scheduled dependency of aplidine, a marine depsipeptide with antitumor activity. Proc Am Assoc Cancer Res. 40:1999;394.
27. Urdiales J.L., Morata P., De Castro I.N., Sanchez-Jimenez F. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett. 102:1996;31-37.
28. Legrue S.J., Sheu T.-L., Carson D.D., Laidlaw J.L., Sanduja S.K. Inhibition of T-lymphocyte proliferation by the cyclic polypeptide didemnin B No inhibition of lymphokine stimulation . Lymphokine Res. 7:1988;21-29.
29. SirDeshpande B.V., Toogood P.L. Mechanism of protein synthesis inhibition by didemnin B in vitro. Biochemistry. 34:1995;9177-9184.
30. Shen G.K., Zukoski C.F., Montgomery D.W. A specific binding site in Nb2 node lymphoma cells mediates the effects of didemnin B, an immunosuppressive cyclic peptide. Int J Immunopharmacol. 14:1992;63-73.
31. Crampton S.L., Adams E.G., Kuentzel S.L., Li L.H., Badiner G., Bhuyan B.K. Biochemical and cellular effects of didemnins A and B. Cancer Res. 44:1984;1796-1801.
32. Crews C.M., Collins J.L., Lane W.S., Snapper M.L., Schreiber S.L. GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1α J Biol Chem. 269:1994;15411-15414.
33. Montgomery D.W., Zukoski C.F. Didemnin B A new immunosuppressive cyclic peptide with potent activity in vitro and in vivo . Transplantation. 40:1985;49-56.
34. 1 cells Inhibition of phosphoinositide metabolism and cell proliferation . J Pharmacol Exp Ther. 271:1994;107-117.
35. Crews C.M., Lane W.S., Schreiber S.L. Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis. Proc Natl Acad Sci USA. 93:1996;4316-4319.
36. Grubb D.R., Wolvetang E.J., Lawen A. Didemnin B induces cell death by apoptosis The fastest induction of apoptosis ever described . Biochem Biophys Res Commun. 215:1995;1130-1136.
37. Beidler D.R., Tewari M.T., Friesen P.D., Poirier G., Dixit V.M. The baculovirus p35 protein inhibits Fas- and tumor necrosis factor-induced apoptosis. J Biol Chem. 270:1995;16526-16528.
38. Tewari M., Dixit V.M. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem. 270:1995;3255-3260.
39. Salvesen G.S., Dixit V.M. Caspases Intracellular signaling by proteolysis . Cell. 91:1997;443-446.
40. Johnson K.L., Vaillant F., Lawen A. Protein tyrosine kinase inhibitors prevent didemnin B-induced apoptosis in HL-60 cells. FEBS Lett. 383:1996;1-5.
41. Vazquez D. Inhibitors of protein synthesis. FEBS Lett. 40:1974;S63-S84.
42. Lobo C., Garcia-Pozo S.G., Nunez de Castro I., Alonso F.J. Effect of dehydrodidemnin B on human colon carcinoma cell lines. Anticancer Res. 17:1997;333-336.
43. Meng L., Sin N., Crews C.M. The antiproliferative agent didemnin B uncompetitively inhibits palmitoyl protein thioesterase. Biochemistry. 37:1998;10488-10492.